S&P 500   2,609.84 (-0.64%)
DOW   22,207.66 (-0.54%)
QQQ   192.11 (+0.04%)
AAPL   257.56 (+1.08%)
FB   168.85 (+1.75%)
MSFT   160.17 (-0.04%)
GOOGL   1,159.49 (+1.15%)
AMZN   1,971.77 (+0.40%)
CGC   14.68 (+2.23%)
NVDA   266.40 (+0.30%)
BABA   193.80 (+1.32%)
MU   43.72 (-1.80%)
GE   7.97 (+1.01%)
TSLA   534.61 (+6.47%)
AMD   46.99 (-1.82%)
T   29.55 (-2.25%)
ACB   0.91 (+2.26%)
F   5.03 (+0.00%)
NFLX   375.37 (+1.19%)
BAC   22.14 (+0.45%)
GILD   75.18 (-0.99%)
PRI   89.90 (-0.89%)
DIS   99.90 (+0.10%)
S&P 500   2,609.84 (-0.64%)
DOW   22,207.66 (-0.54%)
QQQ   192.11 (+0.04%)
AAPL   257.56 (+1.08%)
FB   168.85 (+1.75%)
MSFT   160.17 (-0.04%)
GOOGL   1,159.49 (+1.15%)
AMZN   1,971.77 (+0.40%)
CGC   14.68 (+2.23%)
NVDA   266.40 (+0.30%)
BABA   193.80 (+1.32%)
MU   43.72 (-1.80%)
GE   7.97 (+1.01%)
TSLA   534.61 (+6.47%)
AMD   46.99 (-1.82%)
T   29.55 (-2.25%)
ACB   0.91 (+2.26%)
F   5.03 (+0.00%)
NFLX   375.37 (+1.19%)
BAC   22.14 (+0.45%)
GILD   75.18 (-0.99%)
PRI   89.90 (-0.89%)
DIS   99.90 (+0.10%)
S&P 500   2,609.84 (-0.64%)
DOW   22,207.66 (-0.54%)
QQQ   192.11 (+0.04%)
AAPL   257.56 (+1.08%)
FB   168.85 (+1.75%)
MSFT   160.17 (-0.04%)
GOOGL   1,159.49 (+1.15%)
AMZN   1,971.77 (+0.40%)
CGC   14.68 (+2.23%)
NVDA   266.40 (+0.30%)
BABA   193.80 (+1.32%)
MU   43.72 (-1.80%)
GE   7.97 (+1.01%)
TSLA   534.61 (+6.47%)
AMD   46.99 (-1.82%)
T   29.55 (-2.25%)
ACB   0.91 (+2.26%)
F   5.03 (+0.00%)
NFLX   375.37 (+1.19%)
BAC   22.14 (+0.45%)
GILD   75.18 (-0.99%)
PRI   89.90 (-0.89%)
DIS   99.90 (+0.10%)
S&P 500   2,609.84 (-0.64%)
DOW   22,207.66 (-0.54%)
QQQ   192.11 (+0.04%)
AAPL   257.56 (+1.08%)
FB   168.85 (+1.75%)
MSFT   160.17 (-0.04%)
GOOGL   1,159.49 (+1.15%)
AMZN   1,971.77 (+0.40%)
CGC   14.68 (+2.23%)
NVDA   266.40 (+0.30%)
BABA   193.80 (+1.32%)
MU   43.72 (-1.80%)
GE   7.97 (+1.01%)
TSLA   534.61 (+6.47%)
AMD   46.99 (-1.82%)
T   29.55 (-2.25%)
ACB   0.91 (+2.26%)
F   5.03 (+0.00%)
NFLX   375.37 (+1.19%)
BAC   22.14 (+0.45%)
GILD   75.18 (-0.99%)
PRI   89.90 (-0.89%)
DIS   99.90 (+0.10%)
Log in

NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, Forecast & News

$15.83
+3.61 (+29.54 %)
(As of 03/31/2020 12:30 PM ET)
Today's Range
$14.40
Now: $15.83
$17.50
50-Day Range
$11.00
MA: $16.48
$19.76
52-Week Range
$5.01
Now: $15.83
$21.50
Volume90,719 shs
Average Volume267,124 shs
Market Capitalization$879.20 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.33
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Read More
Kiniksa Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KNSA
CUSIPN/A
CIKN/A
Phone781-439-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.10 per share

Profitability

Net Income$-161,870,000.00

Miscellaneous

Employees111
Market Cap$879.20 million
Next Earnings Date5/7/2020 (Estimated)
OptionableNot Optionable

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.


Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 2.7% and is now trading at $15.67. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kiniksa Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Kiniksa Pharmaceuticals.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) released its earnings results on Wednesday, February, 26th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. View Kiniksa Pharmaceuticals' earnings history.

What price target have analysts set for KNSA?

4 brokers have issued 12 month target prices for Kiniksa Pharmaceuticals' shares. Their forecasts range from $18.00 to $35.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $25.67 in the next year. This suggests a possible upside of 63.8% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals.

What are Wall Street analysts saying about Kiniksa Pharmaceuticals stock?

Here are some recent quotes from research analysts about Kiniksa Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. " (2/5/2020)
  • 2. Wedbush analysts commented, "Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share." (8/14/2019)

Has Kiniksa Pharmaceuticals been receiving favorable news coverage?

Media stories about KNSA stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutKiniksa Pharmaceuticals.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,351,500 shares, an increase of 9.0% from the February 27th total of 1,240,000 shares. Based on an average daily trading volume, of 267,700 shares, the short-interest ratio is currently 5.0 days. Currently, 9.0% of the company's stock are short sold. View Kiniksa Pharmaceuticals' Current Options Chain.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Athenex (ATNX), Global Blood Therapeutics (GBT), Nabriva Therapeutics (NBRV) and Sangamo Therapeutics (SGMO).

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 49)
  • Mr. Stephen Mahoney, Pres & COO (Age 47)
  • Dr. John F. Paolini, Chief Medical Officer (Age 53)
  • Mr. Chris Heberlig, Exec. VP & CFO (Age 43)
  • Mark Ragosa C.F.A., VP of Investor Relations

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $15.67.

How big of a company is Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals has a market capitalization of $870.31 million. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe. View additional information about Kiniksa Pharmaceuticals.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com/.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected]


MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel